Uniqure Nv【0EE0】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

31.50

買値

0.00

売値

0.00

出来高

8,135

0.00 日の範囲 0.00

31.50 52 週間の範囲 31.50

時価総額

1.507B

前日終値

31.50

始値

時刻

6.4192

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

6,090

発行済株式数

47,834,000

配当利回り

PER

-0.98

1 株当たり利益 (EPS)

-6.45

歳入

21.9M

純利益

-308.48M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.uniqure.com

本社

Amsterdam, North Holland, Nld

設立

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0EE0. The last closing price for Uniqure Nv was US$31.50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure Nv currently has 47,834,000 shares in issue. The market capitalisation of Uniqure Nv is US$1.51 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -0.98.

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease ~ Achieved statistically significant...

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to...

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease ~ Designation based on 24-month interim Phase I/II...

期間 †	始値	高値	安値	平均出来高	VWAP
1	31.5	31.5	31.5	10117	31.5	DE
4	31.5	31.5	31.5	4264	31.5	DE
12	31.5	31.5	31.5	6090	31.5	DE
26	31.5	31.5	31.5	11642	31.5	DE
52	31.5	31.5	31.5	6675	31.5	DE
156	31.5	31.5	31.5	2470	31.5	DE
260	31.5	31.5	31.5	1580	31.5	DE

銘柄コード	株価	出来高
SCGLSealand Capital Galaxy Limited	0.54p (80.00%)	36.26M
OBDOxford Biodynamics Plc	2.11p (55.15%)	8.3M
MIRIMirriad Advertising Plc	0.18p (33.33%)	23.04M
CLCOCloudcoco Group Plc	0.26p (30.00%)	3.42M
IESInvinity Energy Systems Plc	15.00p (27.66%)	4.57M
ZNTZentra Group Plc	3.50p (-36.36%)	221.85k
UOGUnited Oil & Gas Plc	0.125p (-34.21%)	123.45M
SYSSysgroup Plc	21.50p (-24.56%)	788.98k
ADAAdams Plc	3.50p (-22.22%)	25k
DSMDowning Strategic Micro-cap Investment Trust Plc	3.70p (-21.28%)	22.32k
ORCPOracle Power Plc	0.0525p (-7.89%)	3.65B
NTVONativo Resources Plc	0.0023p (-8.00%)	1.51B
SYMESupply@me Capital Plc	0.0031p (-10.14%)	1.11B
KEFIKefi Gold And Copper Plc	0.524p (-19.63%)	567.23M
ENETEthernity Networks Ltd	0.1425p (18.75%)	551.92M

銘柄コード

株価

出来高